



This is a repository copy of *An international survey on anti-neutrophil cytoplasmic antibodies (ANCA) testing in daily clinical practice.*

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/132991/>

Version: Supplemental Material

---

**Article:**

Damoiseaux, J., Heijnen, I., Van Campenhout, C. et al. (11 more authors) (2018) An international survey on anti-neutrophil cytoplasmic antibodies (ANCA) testing in daily clinical practice. *Clinical Chemistry and Laboratory Medicine*, 56 (10). pp. 1759-1770. ISSN 1434-6621

<https://doi.org/10.1515/cclm-2017-0306>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Table II. ANCA detection by indirect immunofluorescence.**

	<b>Austria</b>	<b>Belgium</b>	<b>Finland</b>	<b>France</b>	<b>Italy</b>	<b>Netherlands</b>	<b>Portugal</b>	<b>Spain</b>	<b>Sweden</b>	<b>Switzerland</b>	<b>UK &amp; Ireland</b>
<b>ANCA IIF (EtOH)<sup>1</sup></b>	8 (50.0%)	60 (83.3%)	4 (100%)	35 (97.2%)	81 (75.0%)	34 (79.1%)	18 (52.9%)	20 (100%)	4 (36.4%)	19 (90.5%)	51 (86.4%)
<b>ANCA IIF (Form)<sup>2</sup></b>	8 (100%)	50 (83.3%)	2 (50%)	23 (65.7%)	59 (72.8%)	23 (67.6%)	15 (83.3%)	17 (85.0%)	0 (0%)	17 (89.5%)	7 (13.7%)
<b>Screening dilution<sup>3</sup></b>											
<b>1/10</b>	2 (25.0%)	9 (15.0%)	-	4 (11.4%)	29 (37.7%)	5 (14.7%)	7 (38.9%)	4 (20.0%)	-	1 (5.3%)	7 (13.7%)
<b>1/16</b>	-	-	-	-	-	7 (20.6%)	-	-	-	-	-
<b>1/20</b>	5 (62.5%)	31 (51.7%)	4 (100%)	25 (71.4%)	46 (59.7%)	18 (52.9%)	10 (55.6%)	14 (70.0%)	2 (50.0%)	12 (63.2%)	32 (62.7%)
<b>1/40</b>	1 (12.5%)	20 (33.3%)	-	3 (8.6%)	-	4 (11.8%)	1 (5.6%)	2 (10.0%)	-	6 (31.6%)	9 (17.6%)
<b>Titration<sup>3</sup></b>	8 (100%)	40 (66.7%)	4 (100%)	23 (65.7%)	30 (39.0%)	19 (55.9%)	7 (38.9%)	4 (20.0%)	2 (50.0%)	16 (84.2%)	12 (23.5%)
<b>Pattern typing<sup>3</sup></b>	8 (100%)	60 (100%)	4 (100%)	34 (97.1%)	73 (94.8%)	32 (94.1%)	18 (100%)	19 (95.0%)	4 (100%)	19 (100%)	50 (98.0%)

<sup>1</sup> Number of laboratories that perform ANCA by IIF on ethanol-fixed neutrophils (percentage of laboratories that responded).

<sup>2</sup> Number of laboratories that perform ANCA by IIF on formalin-fixed neutrophils (percentage of laboratories that perform ANCA by IIF on ethanol-fixed neutrophils).

<sup>3</sup> Number of laboratories (percentage of laboratories that perform ANCA by IIF on ethanol-fixed neutrophils); in case of the screening dilution percentages may not add-up to 100% because some laboratories use other starting dilutions for ANCA screening.